The secreted PrPC in tumor microenvironment binds to doxorubicin to prevent it from entering the nucleus and intercalating into DNA to induce cell death; and breast cancer patients with high levels of serum PrPC are at high risk of relapse following doxorubicin treatment (13). Here, PRNP is linked to breast cancer.